INTRODUCTION
The incidence of hemolytic disease of the newborn from maternal rhesus (Rh) isoimmunization has decreased markedly since the introduction of Rh immune globulin. 12 However, severe Rh isoimmunization still occurs in women with prior sensitization resulting in fetal anemia, hydrops, and death. Intrauterine transfusions (IUTs) are performed as part of the management of such cases. 12 The development of iron overload in the fetus and newborn secondary to multiple intrauterine intravascular transfusions (IVTs) is poorly recognized. We report an infant who received multiple IVTs and developed cholestasis and portal hypertension due to iron overload.
CASE REPORT
A 2625-g, 33 weeks' gestation girl was born to a 26 year old gravida 5, para 4, blood group A Rh negative woman. Two previous pregnancies had been complicated by Rh isoimmunization, one of which required an exchange transfusion in the neonatal period and one an IUT. At 16 weeks' gestation, because of a rising anti-D antibody titre, a cordocentesis and amniocentesis were performed. This showed that the fetus was Rh positive and that the amniotic fluid delta optical density was 0.25, demonstrating a fetus at high risk of intrauterine death. Starting at 18 weeks, a total of five serial IVTs were performed at three weekly intervals. The fetal hemoglobin before each transfusion ranged between 44 and 60 g/l. A total of 287 ml of blood was transfused.
At 33 weeks' gestation, the mother presented to a peripheral obstetric unit with abdominal pain, vaginal bleeding, and decreased variability on fetal heart rate monitoring. An emergency cesarean section was performed and a baby girl was born with Apgars of 3 and 5 at 1 and 5 minutes respectively. The infant required intubation and chest compressions for resuscitation. On initial physical examination, the infant was noted to be hydropic with marked ascites and subcutaneous edema. There was hepatosplenomegaly with the liver edge palpable 4 cm below the right costal margin and the spleen tip palpable 3 cm below the left costal margin. A chest X-ray showed a ground-glass appearance consistent with hyaline membrane disease and a right pleural effusion. The initial blood gas showed a pH of 6.71 and a base deficit of 15. The initial hemoglobin was 49 g/l. The infant received a packed red blood cell transfusion of 20 ml/kg, a bolus, and infusion of sodium bicarbonate and natural bovine surfactant before transfer to the regional level III neonatal intensive care unit, where a second dose of surfactant was administered. Although the initial bilirubin was only 2.3 mg/dl (39 mol/l) (normal <2.8 mg/dl) a double-volume exchange transfusion was performed to remove Rh antibodies and treat a hemoglobin of 98 g/l.
Subsequently the infant remained ventilator-dependent for 5 weeks secondary to ascites that required intermittent abdominal paracentesis until 7 weeks of age for increased respiratory distress. Conjugated hyperbilirubinemia developed with a peak conjugated
OBJECTIVE:
We report a newborn infant who was successfully treated with chelation therapy having developed severe liver disease secondary to iron overload following multiple intrauterine, intravascular transfusions ( IVTs ) .
STUDY DESIGN:
Case report with review of the literature.
RESULTS:
An infant was born at 33 weeks' gestation having received multiple IVTs for severe rhesus hemolytic disease. At birth there was severe anemia with hydrops and ascites. Severe liver disease was present with portal hypertension, coagulopathy and abnormal liver enzymes. A liver biopsy showed histologic features consistent with iron overload. The serum ferritin was in excess of 4000 g / l. A 7 -week course of deferoxamine resulted in a marked reduction in ferritin levels and significant improvement in liver function.
CONCLUSION:
The possibility of neonatal iron overload following multiple IVTs should be borne in mind. Successful chelation therapy is possible in such cases. (normal 24 to 81) and ALT of 174 IU/l (10 to 33) in the second week of life. There was a marked coagulopathy requiring the administration of fresh frozen plasma (FFP) 40 ml/kg per day and cryoprecipitate 2 units/day for the first week to maintain coagulation parameters within the normal range. Subsequently, FFP and cryoprecipitate were required twice weekly for a further 6 weeks. Thrombocytopenia (platelet count <30,000/ml) was present requiring platelet transfusions daily for the first week and subsequently twice weekly for a further 6 weeks. Cranial ultrasound and computed tomography scans on day 1 showed the presence of a left parieto-occipital hemorrhagic infarct and periventricular leukomalacia. Screening for hepatitis B and C, parvovirus, TORCH, and metabolic disease were negative. A liver biopsy performed at 1 month of age showed histologic features consistent with iron overload (Figure 1 ) with hepatocytes and Kupffer cells with hemosiderin pigment, hemosiderin-laden macrophages in the portal tracts, fibrosis of the portal tracts, bridging fibrosis, and canalicular cholestasis. Staining for alpha-1-antitrypsin was negative. The serum ferritin was 4031 g/l (normal neonatal range 25 to 200 g/l).
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At 5 weeks of age therapy with deferoxamine (25 mg/kg twicedaily intravenous or subcutaneous route) and erythropoietin (150 U/kg subcutaneously three times per week) was started. Coagulopathy resolved within 2 weeks of commencing therapy. Deferoxamine and erythropoietin were discontinued at 12 weeks of age when serum ferritin concentration was less than 1000 g/l. Liver enzymes were normalizing with a total bilirubin of 2 mg/dl (34 mol/l), conjugated bilirubin of 1.1 mg/dl (19 mol/l), AST of 89 IU/l, ALT of 74 IU/l, and hemoglobin of 93 g/l. Ascites resolved within 2 weeks of the commencement of deferoxamine and at the time of discharge there was no evidence of portal hypertension on doppler ultrasound.
A repeat liver biopsy at 4 months of age showed that the iron overload was markedly reduced, although portal and bridging fibrosis remained (Figure 2 ). Liver enzymes were essentially unchanged from the time of discharge.
DISCUSSION
Although no longer a common problem since the introduction of anti-D prophylaxis, Rh isoimmunization still has the potential to cause severe disease of the affected newborn resulting in anemia, fetal hydrops, and death. Advances in fetal and neonatal care have resulted in improved survival for affected infants.
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In utero treatment with IVT through the umbilical vein is increasingly used to manage fetal anemia and hydrops. 24 The possibility of iatrogenic iron overload in the fetus and neonate as a result of frequent IVT is poorly recognized.
In the fetus iron is taken up as transferrin from maternal plasma by the placental trophoblast. 3 Fetal transferrin is highly iron saturated at term. The ferritin level reflects total body iron stores and at birth is relatively high with a level of up to 200 g/l. Subsequently, as the hematocrit falls over the first few months, ferritin levels increase further to approximately 250 g/l before progressively decreasing over the remainder of the first year of life. 3 Conditions such as thalassemia and sickle cell disease, which require multiple transfusions during childhood, result in iron overload with widespread organ damage. As transfused erythrocytes are scavenged by the reticulo-endothelial system, iron accumulates first in tissue macrophages (Kupffer cells, spleen, lymph nodes). 5 If the number of transfusions is limited, the elevated ferritin levels and mild iron overload that results is reversible with time. 6 As there is no active mechanism for iron excretion in the fetus, multiple IUTs may result in iron overload. Nasrat et al. 7 suggested that there is a potential risk of iron overload in Rh alloimmunization fetuses undergoing IUT. Subsequently, Lasker et al. 8 described a newborn with excessive hepatic iron deposition following intraperitoneal IUTs. This case differs from ours because transfusions were begun in the third trimester and were given intraperitoneally rather than intravascularly, no therapy was used to decrease excess iron stores in the infant and a reduction in serum ferritin and hepatic iron overload was not documented.
Iatrogenic neonatal iron overload has a number of clinical similarities with idiopathic neonatal hemochromatosis (INH). 9 However, in INH, an almost universally fatal condition with multiorgan dysfunction, the liver biopsy findings are markedly different with hepatocellular siderosis, giant cell transformation, absence of an inflammatory infiltrate, and sparing of the reticulo-endothelial system. In contrast, the pattern of hepatic injury seen in our patient, with neonatal iron overload due to IVT, was similar to that seen in childhood following multiple transfusions. 5 Erythropoietin is commonly used in the management anemia of prematurity. 10 We used erythropoietin to reduce transfusion requirements and prevent additional iron loading. Deferoxamine therapy is used to mobilize excess iron. 11 Deferoxamine is a chelating agent that complexes with iron from hemosiderin and ferritin to form ferrioxamine. Ferrioxamine is freely water-soluble and is readily excreted by the kidneys giving the urine a characteristic reddish color. Due to the high ferritin level in our case we decided to use deferoxamine, with good results.
This case demonstrates that repeated IVT may lead to iron overload presenting as severe liver disease in the newborn. Following repeated IVTs for severe Rh hemolytic disease; this infant developed severe hepatic dysfunction with evidence of iron overload on liver biopsy. This is the first case of biopsy documented successful chelation therapy for iron overload due to IVT. The possibility of iron overload in the neonate should be borne in mind when frequent IVTs are required.
